ARE

Business Context and Reporting Period

Alexandria Real Estate Equities, Inc. (ARE) is a life science REIT focused on developing, operating, and owning collaborative Megacampus ecosystems in key innovation clusters. This Form 10-Q covers the quarterly period ended March 31, 2025. As of the reporting date, the company held 39.6 million rentable square feet (RSF) of operating properties and 4.0 million RSF under construction, with a total market capitalization of $28.8 billion.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Income Decline: GAAP net income attributable to common stockholders turned to a loss of $(11.6) million, compared to $166.9 million in Q1 2024. This was primarily driven by a $32.2 million impairment charge on a ground lease right-of-use asset in the San Francisco Bay Area and a $50.0 million investment loss (comprising $68.1 million in unrealized losses and $11.2 million in impairments, partially offset by $29.3 million in realized gains).
• Revenue Decrease: Total revenues decreased 1.4% to $758.2 million, largely due to dispositions of real estate assets completed after January 1, 2024, and lease expirations aggregating 768,080 RSF.
• Expense Reductions: General and administrative expenses decreased 35% to $30.7 million due to cost-control initiatives. However, interest expense increased 24.6% to $50.9 million due to new debt issuances and higher construction borrowings.
• Same Property NOI: Same property net operating income (cash basis) increased 5.1%, while GAAP same property NOI decreased 3.1% due to lease expirations.

Guidance, Outlook, and Risks

• 2025 Guidance Update: Management reduced the midpoint of its 2025 FFO per share (as adjusted) guidance by 7 cents to a range of $9.16 to $9.36. The reduction reflects slower-than-anticipated re-leasing of expiring spaces and lease-up of vacancies.
• Capital Recycling: The company expects dispositions and sales of partial interests to range from $1.45 billion to $2.45 billion in 2025. Construction spending guidance midpoint remains at $1.75 billion.
• Dividends: A quarterly dividend of $1.32 per share was declared, representing a 4% increase over the prior year.
• Key Risks:
  • Regulatory & Funding: Potential disruptions to NIH grant funding and FDA workforce reductions could impact tenant operations and R&D budgets.
  • Trade Policy: Recent tariff escalations (including on pharmaceuticals) pose risks of rising construction costs and supply chain disruptions.
  • Legal Proceedings: Ongoing litigation regarding the ACLS-NYC Option Parcel involves potential losses up to $171.1 million, though no impairment was recognized as of March 31, 2025.

Investor Verification Checklist

• Impairment Details: Verify the specific assumptions used in the $32.2 million ground lease impairment and the $11.2 million non-real estate investment impairments.
• Leasing Velocity: Monitor the re-leasing progress of the 768,080 RSF that expired in Q1 2025, as this directly impacts the revised 2025 occupancy and FFO guidance.
• Tariff Impact: Assess the potential cost overruns on the $2.4 billion development pipeline due to new tariffs on construction materials and pharmaceuticals.
• Debt Maturities: Confirm the refinancing strategy for the $600 million unsecured senior notes maturing on April 30, 2025.
• Legal Exposure: Track the status of the lawsuit against NYC Health + Hospitals Corporation regarding the $171.1 million Option Parcel investment.